2022 Caring For Kids With Cancer Evaluation

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree

	5	4	3	2	1
The information and/or skills learned will enhance my professional competence or ability.	The information and/or skills learned will enhance my professional competence or ability. - 5	The information and/or skills learned will enhance my professional competence or ability. - 4	The information and/or skills learned will enhance my professional competence or ability. - 3	The information and/or skills learned will enhance my professional competence or ability. - 2	The information and/or skills learned will enhance my professional competence or ability. - 1
This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients.	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 5	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 4	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 3	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 2	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 1

How confident are you in your ability to: *

5 = High level of confidence 4 = Moderately high level of confidence 3 = Average level of confidence 2 = Low level of confidence 1 = No level of confidence

	5	4	3	2	1
Implement genomic profiling for pediatric cancer treatment?	Implement genomic profiling for pediatric cancer treatment? - 5	Implement genomic profiling for pediatric cancer treatment? - 4	Implement genomic profiling for pediatric cancer treatment? - 3	Implement genomic profiling for pediatric cancer treatment? - 2	Implement genomic profiling for pediatric cancer treatment? - 1
Implement gene therapy to treat blood disorders?	Implement gene therapy to treat blood disorders? - 5	Implement gene therapy to treat blood disorders? - 4	Implement gene therapy to treat blood disorders? - 3	Implement gene therapy to treat blood disorders? - 2	Implement gene therapy to treat blood disorders? - 1

How satisfied or dissatisfied were you with the Speaker's effectiveness in addressing the learning objectives? *

Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied NA= Not Applicable

	5	4	3	2	1	NA
Theodore W. Laetsch, M.D. - Pediatric Precision Oncology	Theodore W. Laetsch, M.D. - Pediatric Precision Oncology - 5	Theodore W. Laetsch, M.D. - Pediatric Precision Oncology - 4	Theodore W. Laetsch, M.D. - Pediatric Precision Oncology - 3	Theodore W. Laetsch, M.D. - Pediatric Precision Oncology - 2	Theodore W. Laetsch, M.D. - Pediatric Precision Oncology - 1	Theodore W. Laetsch, M.D. - Pediatric Precision Oncology - NA
Haydar Frangoul, M.D. - CRISPR- Cas9 For Gene Editing for Sickle Cell Disease B-Thalassemia	Haydar Frangoul, M.D. - CRISPR- Cas9 For Gene Editing for Sickle Cell Disease B-Thalassemia - 5	Haydar Frangoul, M.D. - CRISPR- Cas9 For Gene Editing for Sickle Cell Disease B-Thalassemia - 4	Haydar Frangoul, M.D. - CRISPR- Cas9 For Gene Editing for Sickle Cell Disease B-Thalassemia - 3	Haydar Frangoul, M.D. - CRISPR- Cas9 For Gene Editing for Sickle Cell Disease B-Thalassemia - 2	Haydar Frangoul, M.D. - CRISPR- Cas9 For Gene Editing for Sickle Cell Disease B-Thalassemia - 1	Haydar Frangoul, M.D. - CRISPR- Cas9 For Gene Editing for Sickle Cell Disease B-Thalassemia - NA
Richard Aplenc, M.D. - Tyrosine Kinase Inhibitors in Pediatric Acute Myeloid Leukemia	Richard Aplenc, M.D. - Tyrosine Kinase Inhibitors in Pediatric Acute Myeloid Leukemia - 5	Richard Aplenc, M.D. - Tyrosine Kinase Inhibitors in Pediatric Acute Myeloid Leukemia - 4	Richard Aplenc, M.D. - Tyrosine Kinase Inhibitors in Pediatric Acute Myeloid Leukemia - 3	Richard Aplenc, M.D. - Tyrosine Kinase Inhibitors in Pediatric Acute Myeloid Leukemia - 2	Richard Aplenc, M.D. - Tyrosine Kinase Inhibitors in Pediatric Acute Myeloid Leukemia - 1	Richard Aplenc, M.D. - Tyrosine Kinase Inhibitors in Pediatric Acute Myeloid Leukemia - NA
Kristina Hardy, Ph.D. - Neuropsychological Late Effect of Pediatric Cancer: Characterization Assessment and Intervention	Kristina Hardy, Ph.D. - Neuropsychological Late Effect of Pediatric Cancer: Characterization Assessment and Intervention - 5	Kristina Hardy, Ph.D. - Neuropsychological Late Effect of Pediatric Cancer: Characterization Assessment and Intervention - 4	Kristina Hardy, Ph.D. - Neuropsychological Late Effect of Pediatric Cancer: Characterization Assessment and Intervention - 3	Kristina Hardy, Ph.D. - Neuropsychological Late Effect of Pediatric Cancer: Characterization Assessment and Intervention - 2	Kristina Hardy, Ph.D. - Neuropsychological Late Effect of Pediatric Cancer: Characterization Assessment and Intervention - 1	Kristina Hardy, Ph.D. - Neuropsychological Late Effect of Pediatric Cancer: Characterization Assessment and Intervention - NA
Ziad Khatib, M.D. - Targeted Therapy for Vascular Malformations in Children	Ziad Khatib, M.D. - Targeted Therapy for Vascular Malformations in Children - 5	Ziad Khatib, M.D. - Targeted Therapy for Vascular Malformations in Children - 4	Ziad Khatib, M.D. - Targeted Therapy for Vascular Malformations in Children - 3	Ziad Khatib, M.D. - Targeted Therapy for Vascular Malformations in Children - 2	Ziad Khatib, M.D. - Targeted Therapy for Vascular Malformations in Children - 1	Ziad Khatib, M.D. - Targeted Therapy for Vascular Malformations in Children - NA

Was this course fair, balanced and without commercial bias? *

Yes

No

If you checked "No,” please explain why: *

As a result of what was discussed at this activity what do you intend to do differently? Identify at least two learnings that could be incorporated into your practice *

What are the potential barriers or obstacles that might prevent you from implementing new strategies you learned at this activity? *

Comments

Name

You are here

2022 Caring For Kids With Cancer Evaluation